Posting of EGM Notice and Explanatory Memorandum
Wellnex Life Limited has posted the Notice of Extraordinary General Meeting and explanatory memorandum to shareholders, which will be held on September 8, 2026. The EGM is to seek shareholder approval for the proposed sale and disposal of the Pain Away Business to Mentholatum Australasia Pty Ltd, a transaction requiring approval under Rule 15 of the AIM Rules.
Select text to share a quote on X · sign in to keep highlights & notes in your WNX notes
Wellnex Life Limited (ASX/AIM: WNX) (the "Company") announces that, further to the Company's announcement on 6 August 2026, the Notice of Extraordinary General Meeting ("EGM") and explanatory memorandum has been posted to shareholders.
The EGM will be held at Level 23, Rialto South Tower, 525 Collins Street, Melbourne VIC 3000 Australia, at 10:00 am AEST (1:00 am BST) on 8 September 2026. The purpose of the EGM is for the Company to seek the necessary shareholder approval required in connection with the Company's proposed sale and disposal of the Pain Away Business to Mentholatum Australasia Pty Ltd for the purposes of Rule 15 of the AIM Rules, and all other purposes.
Copies of the Notice of EGM and explanatory memorandum are available from the Company's website: https://wellnexlife.investorportal.com.au/
Capitalised terms used but not defined in this announcement will have the same meaning given to them in the Notice of EGM and explanatory memorandum.
This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.